Telemedicine pioneer Teladoc Health (NYSE: TDOC) had an incredible 2020. The pandemic turned the small but growing remote virtual care niche of the healthcare industry into a basic staple. But as the economy has begun to reopen, some shareholders have worried Teladoc's progress might suddenly reverse course. Helped by its transformational acquisition of Livongo Health last autumn, Teladoc has dispelled those fears with an outlook for revenue to nearly double again in 2021.
Amwell (NYSE: AMWL) on the other hand -- not so much. Its fourth-quarter 2020 results were decent enough, but the outlook for the new year implies the health technologist's expansion will slow to a snail's pace as it laps initial effects from the pandemic. Here's why it's best to practice patience before buying the dip in Amwell.
Image source: Getty Images.
For further details see:
Teladoc Shareholders Worried About Post-Pandemic Blues, But It's Amwell That's Seeing the Slowdown